Vestmark Advisory Solutions Inc. Lowers Position in Twist Bioscience Corporation $TWST

Vestmark Advisory Solutions Inc. lessened its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 40.7% during the third quarter, Holdings Channel.com reports. The firm owned 117,249 shares of the company’s stock after selling 80,348 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Twist Bioscience were worth $3,299,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC raised its stake in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth $97,000. CWM LLC raised its stake in shares of Twist Bioscience by 61.4% in the third quarter. CWM LLC now owns 4,331 shares of the company’s stock worth $122,000 after buying an additional 1,648 shares during the period. AXQ Capital LP bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at $226,000. Finally, Corton Capital Inc. purchased a new position in Twist Bioscience in the 2nd quarter worth approximately $244,000.

Insider Transactions at Twist Bioscience

In other news, insider Dennis Cho sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the sale, the insider owned 138,581 shares of the company’s stock, valued at approximately $6,919,349.33. This trade represents a 3.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Robert F. Werner sold 7,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $45.65, for a total transaction of $319,550.00. Following the completion of the transaction, the chief accounting officer owned 58,738 shares of the company’s stock, valued at $2,681,389.70. This represents a 10.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 36,609 shares of company stock valued at $1,665,151. 3.08% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on TWST. Stephens initiated coverage on Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective on the stock. Robert W. Baird set a $50.00 price target on Twist Bioscience in a research note on Tuesday, February 3rd. Barclays boosted their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Evercore upped their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.88.

Twist Bioscience Trading Down 1.0%

TWST stock opened at $48.09 on Tuesday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $57.88. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -37.57 and a beta of 2.24. The business’s 50-day moving average is $40.93 and its 200 day moving average is $33.37. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company’s revenue for the quarter was up 16.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.